AngioDynamics (ANGO) Q2 2024: $15M Cost Takeout Targets FY27 Profitability Amid Thrombectomy Softness
AngioDynamics’ Q2 revealed a business in active transformation, with a decisive $15 million annualized cost-reduction plan to fully outsource manufacturing by FY27, aiming for long-awaited profitability. While MedTech and Arion platforms posted growth, mechanical thrombectomy underperformed, forcing a guidance reset and underscoring the need for execution on pipeline launches and margin expansion. Investors now face a two-year window of operational transition and margin volatility, with success hinging on regulatory wins and commercial acceleration in large, underpenetrated markets.
Summary
- Manufacturing Overhaul: Full outsourcing plan targets $15 million annual savings and FY27 profitability.
- Thrombectomy Drag: Mechanical thrombectomy weakness triggers guidance cut and exposes growth risk.
- Pipeline Execution Focus: Regulatory approvals and new product launches will dictate near-term trajectory.
Business Overview
AngioDynamics develops and sells minimally invasive medical devices and technology platforms for vascular and oncology applications. The business is organized into two main segments: MedTech, high-growth medical technology platforms (e.g., Arion, AngioVac, AlphaVac, NanoKnife), and MedDevice, legacy medical device products (e.g., angiographic catheters, ports). Revenue is generated through direct sales to hospitals and clinics, with a growing mix from higher-margin MedTech products, which comprised 32.1% of Q2 revenue.
Performance Analysis
Q2 revenue grew 2.7% year-over-year, with MedTech up 3.5% and MedDevice up 2.3%. The Arion platform, laser-based vascular therapy, delivered 12.9% growth, hitting a $100 million cumulative milestone since launch. However, mechanical thrombectomy, clot-removal devices, declined 4.7%, with both AngioVac and AlphaVac underperforming due to procedural softness and competitive headwinds. International sales outpaced the domestic market, growing 12.6%—a bright spot driven by both segments.
Gross margin compressed 80 basis points to 50.9%, with MedTech margin at 62.4% and MedDevice at 45.5%. The margin pressure stemmed from sales mix, hardware placements, and lingering inflation, partially offset by lower freight and labor costs. Operating cash flow was positive, and the balance sheet remained debt-free, but the company posted a net loss and lowered its full-year guidance on both revenue and EPS, citing persistent thrombectomy weakness and manufacturing transition impacts.
- MedTech Mix Shift: MedTech’s share of total revenue continues to rise, supporting long-term margin ambitions.
- Arion Platform Momentum: Arion’s double-digit growth and milestone reinforce its role as a core growth engine.
- Thrombectomy Setback: AlphaVac and AngioVac sales decline exposes sensitivity to procedural volume and regulatory timing.
Despite solid performance in certain platforms, the overall growth profile remains uneven, and near-term profitability is deferred pending execution on structural cost reduction and product pipeline milestones.
Executive Commentary
"With these moves, we will remain focused on generating continued growth across both our med tech and med device businesses while simultaneously driving margin expansion. Importantly, when the dust settles from our initiatives at the end of our two-year plan, We expect to achieve full-year profitability in FY2027."
Jim Clemmer, President and Chief Executive Officer
"This morning's announcement regarding restructuring our manufacturing footprint and transitioning our upstate New York manufacturing operations to a fully outsourced model will address these structural cost limitations, meaningfully improve gross margins, and lead to full-year adjusted EPS profitability in FY27."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Full Manufacturing Outsourcing
AngioDynamics is executing a two-year plan to fully outsource manufacturing, transitioning from company-owned sites in upstate New York to third-party partners, including established operations in Costa Rica. This move is expected to deliver $15 million in annual savings by FY27, simplify the supply chain, and enable sharper focus on high-margin, high-growth MedTech platforms.
2. MedTech Portfolio Optimization
Leadership continues to evaluate and rationalize its MedDevice portfolio, seeking to divest or restructure lower-growth SKUs and redeploy resources into differentiated MedTech platforms. This ongoing shift is designed to accelerate the MedTech mix, which supports margin expansion and aligns R&D with platforms that offer clinical and commercial leverage.
3. Pipeline and Regulatory Catalysts
Success in the next 18 months hinges on the timing and adoption of new product launches and regulatory approvals, especially for AlphaVac’s pulmonary embolism (PE) indication and Arion’s CE mark and radial catheter launch. Management is preparing for six Arion launches in 2024, and expects FDA and EU approvals to unlock larger addressable markets.
4. International Expansion
International markets delivered double-digit growth, supported by clinical symposia and new distributor relationships. With CE marks pending for key products, global expansion is positioned as a growth lever, particularly as U.S. markets face reimbursement and procedural headwinds.
5. Commercial Execution and Sales Force Readiness
Recent investments in sales leadership, training, and clinical education aim to prepare the organization for upcoming product launches and market expansion. Management is acutely aware that commercial readiness will be critical as new indications and devices come online.
Key Considerations
This quarter marks a strategic inflection for AngioDynamics, as management bets on structural cost reduction and pipeline execution to drive a return to profitability and sustainable growth. Investors must weigh near-term volatility against the potential for long-term value creation.
Key Considerations:
- Margin Expansion Hinges on Execution: Realizing $15 million in cost savings and shifting to a higher MedTech mix are prerequisites for hitting FY27 profitability targets.
- Regulatory and Launch Timelines Are Critical: Delays in AlphaVac PE or Arion approvals could prolong growth and margin headwinds.
- Thrombectomy Remains a Swing Factor: Mechanical thrombectomy’s underperformance exposes the business to competitive and procedural volatility.
- International Growth Offsets Domestic Headwinds: Double-digit international growth provides diversification, but global regulatory risks remain.
- Balance Sheet Strength Buys Time: Zero debt and ample cash support the transition, but persistent losses are unsustainable without execution on cost and growth levers.
Risks
Near-term risks include execution missteps in the manufacturing transition, regulatory delays for key pipeline products, and continued procedural softness in core thrombectomy markets. Further margin volatility is likely until the full outsourcing transition is complete, and competition in both MedTech and MedDevice segments remains intense. Reimbursement and pre-authorization headwinds, especially in the U.S., could dampen procedural volumes and slow adoption of new technologies.
Forward Outlook
For Q3, AngioDynamics guided to:
- Continued revenue softness in thrombectomy, with MedTech growth revised to 10%–15% (down from 20%–25%)
- Gross margin in the 49%–51% range, reflecting mix and transition costs
For full-year 2024, management lowered guidance:
- Revenue: $320–$325 million (prior $328–$333 million)
- Adjusted EPS loss: $0.35–$0.42
Management highlighted several factors that will shape the next quarters:
- Regulatory milestones for AlphaVac PE and Arion expected mid-to-late 2024
- Six product launches for Arion in 2024, including the radial catheter
Takeaways
AngioDynamics is betting on a bold cost transformation and pipeline-driven growth, but faces a two-year window of margin and execution risk before profitability is in sight.
- Structural Cost Reset: The $15 million annual savings target is material, but requires flawless execution and transition management to deliver the anticipated margin uplift by FY27.
- Pipeline-Dependent Growth: Regulatory approvals and commercial launches in thrombectomy and Arion are essential to reaccelerate growth and offset MedDevice drag.
- Investor Watchpoint: Track the cadence of MedTech mix gains, margin progression, and pipeline milestones for early signs of inflection or further delay.
Conclusion
AngioDynamics is at a crossroads, with a clear path to profitability built on cost discipline and pipeline execution, but near-term volatility and growth risk remain pronounced. The next 18–24 months will be decisive in determining whether the transformation delivers sustainable value.
Industry Read-Through
AngioDynamics’ transition to a fully outsourced manufacturing model reflects a broader MedTech trend toward asset-light operations and cost rationalization in response to margin compression and inflationary pressures. The quarter’s procedural softness and reimbursement headwinds echo challenges faced by peers in vascular and interventional devices, underscoring the importance of differentiated clinical data and regulatory agility. Success with AlphaVac and Arion launches could signal renewed growth for device innovators targeting large, underpenetrated markets, but the risk of pipeline-driven volatility remains a sector-wide theme. Investors across MedTech should watch for execution on cost takeout, mix shift, and regulatory catalysts as key levers for re-rating and margin recovery.